loading...| Preferred Name |
Everolimus |
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C48387 |
| Accepted_Therapeutic_Use_For |
neuroendocrine tumors (NET) of gastrointestinal (GI), lung or pancreatic origin |
| ALT_DEFINITION |
A drug used to treat advanced kidney cancer that did not respond to treatment with certain other anticancer drugs. It is also being studied in the treatment of other types of cancer. Afinitor stops cancer cells from dividing and may block the growth of new blood vessels that tumors need to grow. It also decreases the body's immune responses. It is a type of immunosuppressant and a type of antiangiogenesis agent. |
| CAS_Registry |
159351-69-6 |
| Chemical_Formula |
C53H83NO14 |
| code |
C48387 |
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C177537 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 |
| Contributing_Source |
CTRP GDC FDA |
| DEFINITION |
A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production. (NCI05) |
| Display_Name |
Everolimus |
| FDA_UNII_Code |
9HW64Q8G6G |
| FULL_SYN |
RAD 001 Zortress Votubia Afinitor RAD001 everolimus RAD-001 Everolimus (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone EVEROLIMUS 42-O-(2-Hydroxy)ethyl Rapamycin Certican |
| Has_Target | |
| Is_Value_For_GDC_Property | |
| label |
Everolimus |
| Legacy Concept Name |
Everolimus |
| Maps_To |
Everolimus |
| NCI_Drug_Dictionary_ID |
372905 |
| NSC Number |
733504 |
| PDQ_Closed_Trial_Search_ID |
372905 |
| PDQ_Open_Trial_Search_ID |
372905 |
| Preferred_Name |
Everolimus |
| prefixIRI |
Thesaurus:C48387 |
| prefLabel |
Everolimus |
| Semantic_Type |
Pharmacologic Substance |
| UMLS_CUI |
C0541315 |
| subClassOf |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C574 |